{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T04:51:45Z","timestamp":1684471905657},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T00:00:00Z","timestamp":1443657600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hypertens Res"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1038\/hr.2015.105","type":"journal-article","created":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T06:32:35Z","timestamp":1443681155000},"page":"802-803","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Metabolic approaches to antihypertensive treatment in diabetic patients"],"prefix":"10.1038","volume":"38","author":[{"given":"Arrigo F","family":"Cicero","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuliano","family":"Tocci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,10,1]]},"reference":[{"key":"BFhr2015105_CR1","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1111\/jch.12373","volume":"16","author":"D Lemogoum","year":"2014","unstructured":"Lemogoum D . Challenge for hypertension prevention and control worldwide: the time for action. J Clin Hypertens 2014; 16: 554\u2013556.","journal-title":"J Clin Hypertens"},{"key":"BFhr2015105_CR2","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1097\/HJH.0b013e328362a34a","volume":"31","author":"C Borghi","year":"2013","unstructured":"Borghi C, Cicero AF . How to avoid the depression of the adherence to antihypertensive treatment? J Hypertens 2013; 31: 1362\u20131363.","journal-title":"J Hypertens"},{"key":"BFhr2015105_CR3","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1038\/hr.2011.94","volume":"34","author":"AF Cicero","year":"2011","unstructured":"Cicero AF, Ertek S . Hypertension and diabetes incidence: confounding factors. Hypertens Res 2011; 34: 1069\u20131070.","journal-title":"Hypertens Res"},{"key":"BFhr2015105_CR4","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1097\/HJH.0b013e328364ca4c","volume":"31","author":"ESH\/ESC Task Force for the Management of Arterial Hypertension","year":"2013","unstructured":"ESH\/ESC Task Force for the Management of Arterial Hypertension. Practice guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC): ESH\/ESC Task Force for the Management of Arterial Hypertension. J Hypertens 2013; 31: 1925\u20131938.","journal-title":"J Hypertens"},{"key":"BFhr2015105_CR5","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1038\/hr.2015.57","volume":"38","author":"G Derosa","year":"2015","unstructured":"Derosa G, Querci F, Franzetti I, Ragonesi PD, D\u2019Angelo A, Maffioli P . Comparison of the effects of barnidipine+losartan compared to telmisartan+hydrochlorothiazide on several parameters of insulin sensitivity in patients with hypertension and type 2 diabetes mellitus. Hypertens Res 2015; 38: 690\u2013694.","journal-title":"Hypertens Res"},{"key":"BFhr2015105_CR6","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1124\/pr.112.007278","volume":"65","author":"MC Michel","year":"2013","unstructured":"Michel MC, Foster C, Brunner HR, Liu L . A systematic comparison of the properties of clinically used angiotensin II type 1 receptor antagonists. Pharmacol Rev 2013; 65: 809\u2013848.","journal-title":"Pharmacol Rev"},{"key":"BFhr2015105_CR7","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1517\/14656566.2012.708733","volume":"13","author":"C Borghi","year":"2012","unstructured":"Borghi C, Cicero AF . Hypertension: management perspectives. Expert Opin Pharmacother 2012; 13: 1999\u20132003.","journal-title":"Expert Opin Pharmacother"},{"key":"BFhr2015105_CR8","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1038\/jhh.2014.115","volume":"29","author":"G Tocci","year":"2015","unstructured":"Tocci G, Cicero AF, Salvetti M, Francia P, Ferrucci A, Borghi C, Volpe M . Attitudes and preferences for the clinical management of hypertension and hypertension-related cardiac disease in general practice: results of the Italian Hypertension and Heart Survey. J Hum Hypertens 2015; 29: 409\u2013416.","journal-title":"J Hum Hypertens"},{"key":"BFhr2015105_CR9","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.metabol.2014.10.016","volume":"64","author":"M Bl\u00fcher","year":"2015","unstructured":"Bl\u00fcher M, Mantzoros CS . From leptin to other adipokines in health and disease: facts and expectations at the beginning of the 21st century. Metabolism 2015; 64: 131\u2013145.","journal-title":"Metabolism"},{"key":"BFhr2015105_CR10","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/1758-5996-5-35","volume":"5","author":"AL Price","year":"2013","unstructured":"Price AL, Lingvay I, Szczepaniak EW, Wiebel J, Victor RG, Szczepaniak LS . The metabolic cost of lowering blood pressure with hydrochlorothiazide. Diabetol Metab Syndr 2013; 5: 35.","journal-title":"Diabetol Metab Syndr"},{"key":"BFhr2015105_CR11","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1038\/hr.2012.196","volume":"36","author":"H Takagi","year":"2013","unstructured":"Takagi H, Mizuno Y, Yamamoto H, Goto SN, Umemoto T . All-Literature Investigation of Cardiovascular Evidence Group. Effects of telmisartan therapy on interleukin-6 and tumor necrosis factor-alpha levels: a meta-analysis of randomized controlled trials. Hypertens Res 2013; 36: 368\u2013373.","journal-title":"Hypertens Res"},{"key":"BFhr2015105_CR12","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1038\/hr.2013.157","volume":"37","author":"D Mikami","year":"2014","unstructured":"Mikami D, Kimura H, Kamiyama K, Torii K, Kasuno K, Takahashi N, Yoshida H, Iwano M . Telmisartan activates endogenous peroxisome proliferator-activated receptor-\u03b4 and may have anti-fibrotic effects in human mesangial cells. Hypertens Res 2014; 37: 422\u2013431.","journal-title":"Hypertens Res"}],"container-title":["Hypertension Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/hr2015105.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/hr2015105","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/hr2015105.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T17:14:51Z","timestamp":1684430091000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/hr2015105"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10,1]]},"references-count":12,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["BFhr2015105"],"URL":"https:\/\/doi.org\/10.1038\/hr.2015.105","relation":{},"ISSN":["0916-9636","1348-4214"],"issn-type":[{"value":"0916-9636","type":"print"},{"value":"1348-4214","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,10,1]]},"assertion":[{"value":"1 October 2015","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}